U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.
How should efficacy of new adjuvant therapies be evaluated in colorectal cancer? Marc Buyse, ScD IDDI, Brussels, Belgium Based on Daniel Sargent’s talks.
Axel Grothey, MD Professor of Oncology Mayo Clinic College of Medicine Rochester, MN
